| Species |
Human |
| Protein Construction |
ULBP-1 (Gly26-Pro215)_x000D_
Accession # Q9BZM6 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1 EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized ULBP-1, His & Avi, Human at 5μg/ml (100 μl/well) on the plate can bind Human NKG2D, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
25.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 28-35 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in 20 mM PB, 0.5 M NaCl, 0.1 M L-arginine (pH 8.0). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
ULBP-1, or UL16-binding protein 1, is a protein that plays a significant role in the immune system, particularly in the recognition and elimination of abnormal cells, such as those found in cancer. It is a ligand for the NKG2D receptor, which is expressed on the surface of natural killer (NK) cells and certain T cells. The interaction between ULBP-1 and NKG2D can activate these immune cells, leading to the destruction of target cells. |
| Synonyms |
ALCAN-beta; NKG2D ligand 1; N2DL-1; NKG2DL1; MULT-1; NKG2DL; AET1I; ULBP1; ULBP-1;ALCAN-β |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
